P=N/A, N=6, Active, not recruiting, Australasian Gastro-Intestinal Trials Group | Recruiting --> Active, not recruiting | Phase classification: P2 --> PN/A | N=75 --> 6 | Trial completion date: Jun 2025 --> Dec 2027 | Trial primary completion date: Jun 2024 --> Dec 2025

Systemic bevacizumab remains the most mature systemic option with consistent real-world evidence and published dosing guidance. HPV-specific immunotherapy has recently transformed adult RRP management with an FDA-approved, short-course treatment option; ongoing studies will clarify optimal sequencing with bevacizumab and the role of checkpoint inhibition.

These results suggest that activation of T cells and macrophages are associated with a favorable clinical response to atezolizumab + bevacizumab + SBRT. Moreover, CD8 TRM, CD8 exhausted T cells, and CXCL10+ macrophages may serve as potential biomarkers of response to atezolizumab + bevacizumab + SBRT treatment and potentially aid in tailored, precision medicine for individual patients.

P3, N=88, Active, not recruiting, University of Giessen | Recruiting --> Active, not recruiting

Irinotecan is a cornerstone therapy for metastatic colorectal cancer (CRC); however, the poor solubility and instability of its active metabolite, SN38, limit its therapeutic efficacy...In the azoxymethane/dextran sodium sulfate-induced colitis-associated CRC model, intraperitoneal administration of either free SN38 or SN38-PLGA five times per week, combined with bevacizumab, significantly reduced tumor numbers compared with saline controls (7.2 vs. 7.7 vs. 14.8, p < 0.001), with comparable efficacy between the two treatment groups (p = 0.987)...In conclusion, PLGA encapsulation preserves antitumor efficacy while reducing the severity of colitis. SN38-PLGA represents a promising therapeutic platform for colorectal cancer, with the potential to reduce dosing frequency and gastrointestinal toxicity.

P2/3, N=168, Active, not recruiting, Compass Therapeutics | Completed --> Active, not recruiting | Trial completion date: Jan 2026 --> Dec 2026 | Trial primary completion date: Jan 2026 --> Dec 2026

Despite adjuvant carboplatin, paclitaxel, and bevacizumab followed by maintenance therapy, she developed platinum-resistant progression with peritoneal and nodal disease and is currently receiving additional systemic therapy with poor response. This case highlights the potential for malignant transformation in benign-appearing SCT-NOS and underscores the importance of counseling patients on the rare risk of recurrence and the need for novel therapeutic strategies in recurrent disease. Integration of clinical, pathologic, and molecular data may improve risk stratification and management of this rare tumor.

We describe a 75-year-old man with advanced lung adenocarcinoma who developed multiple bleeding pyogenic granulomas during docetaxel plus ramucirumab therapy. This intra-patient contrast suggests that VEGFR-2 blockade and VEGF ligand inhibition may have different effects on paradoxical vascular proliferative lesions. Clinicians should recognize this rare toxicity and consider switching anti-angiogenic strategy in selected cases.

P2/3, N=690, Recruiting, Bristol-Myers Squibb

P2/3, N=990, Recruiting, Bristol-Myers Squibb

Although causality cannot be established, these findings raise the hypothesis that PRES could be a class effect of angiogenesis inhibitors and call for ongoing epidemiological surveillance and timely multiprofessional management of hypertension as a risk-minimization strategy. The potential modulatory role of FGFR4 deserves further mechanistic translational studies.

Patients received combination therapy with nab-paclitaxel, bevacizumab, and toripalimab (Q3W) at Nanjing Drum Tower Hospital. Furthermore, this triplet therapy combined with radiotherapy significantly improves PFS. Preliminary biomarker analysis suggests that patients with liver metastasis, MET or NF1 mutations may be less likely to benefit from this treatment regimen.